EA201890960A1 - Натуральные киллеры и клетки ilc3 и их применение - Google Patents
Натуральные киллеры и клетки ilc3 и их применениеInfo
- Publication number
- EA201890960A1 EA201890960A1 EA201890960A EA201890960A EA201890960A1 EA 201890960 A1 EA201890960 A1 EA 201890960A1 EA 201890960 A EA201890960 A EA 201890960A EA 201890960 A EA201890960 A EA 201890960A EA 201890960 A1 EA201890960 A1 EA 201890960A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cells
- ilc3
- methods
- ilc3 cells
- application
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 abstract 5
- 210000000822 natural killer cell Anatomy 0.000 abstract 4
- 208000036142 Viral infection Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000009385 viral infection Effects 0.000 abstract 2
- 230000004069 differentiation Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/90—Polysaccharides
- C12N2501/91—Heparin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Developmental Biology & Embryology (AREA)
Abstract
В рамках настоящего изобретения предусматриваются способы получения натуральных киллеров (NK) и/или клеток ILC3 с использованием трехстадийного способа увеличения в количестве и дифференцировки с использованием среды, содержащей факторы, мобилизующие стволовые клетки. Также в рамках настоящего изобретения предусматриваются способы подавления пролиферации опухолевых клеток с использованием NK-клеток и/или клеток ILC3 и популяций NK-клеток и/или клеток ILC3, полученных трехстадийными способами, описанными в настоящем описании, а также способы лечения индивидуумов, имеющих злокачественную опухоль или вирусную инфекцию, включающий введение индивидууму, имеющему злокачественную опухоль или вирусную инфекцию NK-клеток и/или клеток ILC3 и популяций NK-клеток и/или клеток ILC3, полученных трехстадийными способами, описанными в настоящем описании.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562242246P | 2015-10-15 | 2015-10-15 | |
US201562272984P | 2015-12-30 | 2015-12-30 | |
US201662403571P | 2016-10-03 | 2016-10-03 | |
PCT/US2016/056988 WO2017066530A1 (en) | 2015-10-15 | 2016-10-14 | Natural killer cells and ilc3 cells and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201890960A1 true EA201890960A1 (ru) | 2018-10-31 |
Family
ID=58517926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201890960A EA201890960A1 (ru) | 2015-10-15 | 2016-10-14 | Натуральные киллеры и клетки ilc3 и их применение |
Country Status (17)
Country | Link |
---|---|
US (2) | US20180346877A1 (ru) |
EP (1) | EP3362075B1 (ru) |
JP (3) | JP2018535666A (ru) |
KR (1) | KR20180059555A (ru) |
CN (1) | CN109310710A (ru) |
AU (1) | AU2016340005B2 (ru) |
BR (1) | BR112018007538A2 (ru) |
CA (1) | CA3002066A1 (ru) |
CO (1) | CO2018004937A2 (ru) |
EA (1) | EA201890960A1 (ru) |
IL (1) | IL258666B2 (ru) |
MX (1) | MX2018004600A (ru) |
MY (1) | MY201637A (ru) |
NZ (1) | NZ741612A (ru) |
SG (2) | SG10201912576PA (ru) |
TW (1) | TW201732037A (ru) |
WO (1) | WO2017066530A1 (ru) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
CA3077325A1 (en) * | 2017-09-28 | 2019-04-04 | Celularity Inc. | Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody |
EP3755355A4 (en) * | 2018-02-20 | 2022-01-05 | Universite De Montreal | IN VIVO EXPANSION OF NK AND DC CELLS TO PROVIDE AN IMMUNE RESPONSE |
CN108486054B (zh) * | 2018-04-12 | 2022-04-19 | 平安爱普德(北京)生物技术有限公司 | 一种体外扩增i型天然细胞毒性淋巴细胞ilc1/nk的方法 |
KR20210111762A (ko) * | 2018-11-30 | 2021-09-13 | 셀룰래리티 인코포레이티드 | 신규 방향족 화합물을 사용한 자연 살해 세포 및 ilc3 세포의 증식 |
WO2020231200A1 (ko) * | 2019-05-15 | 2020-11-19 | 오정훈 | 효율적 자연살해세포 배양방법 및 이의 배지첨가 키트 |
WO2020252464A1 (en) * | 2019-06-14 | 2020-12-17 | Celularity Inc. | Populations of natural killer cells for treating cancers |
CA3145510A1 (en) * | 2019-07-29 | 2021-02-04 | Deverra Therapeutics Inc. | Nk cell composition and preparations for immunotherapy and methods for their production |
WO2021119834A1 (en) * | 2019-12-18 | 2021-06-24 | Universite De Montreal | Modulators of cullin 3 adaptor kbtbd4 as anti-cancer compounds |
WO2021155312A1 (en) * | 2020-01-29 | 2021-08-05 | Celularity Inc. | Placental derived natural killer cells for treatment of coronavirus infections |
US20210260115A1 (en) * | 2020-02-21 | 2021-08-26 | FullHope Biomedical Co., Ltd. | Modified natural killer cells, pharmaceutical composition, manufacturing method thereof, and method of using the same |
JP2021136883A (ja) * | 2020-03-02 | 2021-09-16 | 株式会社ガイアバイオメディシン | 高活性nk細胞の処理方法 |
CN112285083B (zh) * | 2020-10-28 | 2022-01-07 | 上海睿钰生物科技有限公司 | 一种细胞杀伤效力的评价方法 |
CN112251406B (zh) * | 2020-10-30 | 2023-06-09 | 曹峰林 | 一种nk细胞活化阶段的外泌体分选方法 |
US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
EP4271798A1 (en) | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions and methods for differentiating stem cells into nk cells |
WO2023038037A1 (ja) * | 2021-09-08 | 2023-03-16 | 株式会社ガイアバイオメディシン | 細胞の処理方法 |
CN117511867B (zh) * | 2023-10-07 | 2024-08-06 | 深圳泽医细胞治疗集团有限公司 | 一种靶向肺部且高表达nkg2d的nk细胞的培养试剂盒及其应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5709859A (en) * | 1991-01-24 | 1998-01-20 | Bristol-Myers Squibb Company | Mixed specificity fusion proteins |
PE20100362A1 (es) * | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
WO2012075412A1 (en) * | 2010-12-03 | 2012-06-07 | Michael Verneris | Generation of natural killer cells and lymphoid tissue inducer-like (lti-like) nk-22 cells |
ES2856825T3 (es) * | 2011-03-18 | 2021-09-28 | Glycostem Therapeutics B V | Generación de células NK y progenitores de células NK |
US9409906B2 (en) * | 2012-01-27 | 2016-08-09 | Universite De Montreal | Pyrimido[4,5-B]indole derivatives and use thereof in the expansion of hematopoietic stem cells |
ES2771248T3 (es) | 2012-02-08 | 2020-07-06 | Glycostem Therapeutics B V | Diferenciación de células NK ex vivo de células hematopoyéticas CD34+ |
MX2015001871A (es) * | 2012-08-13 | 2015-09-21 | Anthrogenesis Corp | Celulas asesinas naturales y usos de las mismas. |
US9074186B2 (en) * | 2012-08-15 | 2015-07-07 | Boston Medical Center Corporation | Production of red blood cells and platelets from stem cells |
EP3041494A4 (en) * | 2013-09-05 | 2017-10-18 | Sanford-Burnham Medical Research Institute | Modulation of gamma delta t cells |
EA201791443A1 (ru) * | 2014-12-31 | 2018-01-31 | Антродженезис Корпорейшн | Естественные киллерные клетки и их применения |
EP3350316B1 (en) * | 2015-09-15 | 2024-05-08 | Stichting Radboud universitair medisch centrum | IMPROVED METHOD FOR EX VIVO EXPANSION CD34+HSPCs INTO NK CELLS USING AN ARYL HYDROCARBON RECEPTOR ANTAGONIST |
-
2016
- 2016-10-14 EA EA201890960A patent/EA201890960A1/ru unknown
- 2016-10-14 MY MYPI2018701476A patent/MY201637A/en unknown
- 2016-10-14 BR BR112018007538A patent/BR112018007538A2/pt active Search and Examination
- 2016-10-14 SG SG10201912576PA patent/SG10201912576PA/en unknown
- 2016-10-14 JP JP2018519316A patent/JP2018535666A/ja active Pending
- 2016-10-14 SG SG11201803117YA patent/SG11201803117YA/en unknown
- 2016-10-14 NZ NZ741612A patent/NZ741612A/en unknown
- 2016-10-14 WO PCT/US2016/056988 patent/WO2017066530A1/en active Application Filing
- 2016-10-14 MX MX2018004600A patent/MX2018004600A/es unknown
- 2016-10-14 IL IL258666A patent/IL258666B2/en unknown
- 2016-10-14 TW TW105133346A patent/TW201732037A/zh unknown
- 2016-10-14 AU AU2016340005A patent/AU2016340005B2/en active Active
- 2016-10-14 EP EP16856249.4A patent/EP3362075B1/en active Active
- 2016-10-14 CN CN201680074724.8A patent/CN109310710A/zh active Pending
- 2016-10-14 US US15/768,505 patent/US20180346877A1/en not_active Abandoned
- 2016-10-14 CA CA3002066A patent/CA3002066A1/en active Pending
- 2016-10-14 KR KR1020187013666A patent/KR20180059555A/ko not_active Application Discontinuation
-
2018
- 2018-05-09 CO CONC2018/0004937A patent/CO2018004937A2/es unknown
-
2021
- 2021-10-19 JP JP2021171231A patent/JP2022023148A/ja active Pending
-
2022
- 2022-11-16 US US18/056,088 patent/US20230142803A1/en active Pending
-
2023
- 2023-09-07 JP JP2023145605A patent/JP2023171766A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
MY201637A (en) | 2024-03-06 |
IL258666A (en) | 2018-06-28 |
IL258666B2 (en) | 2024-09-01 |
WO2017066530A1 (en) | 2017-04-20 |
AU2016340005B2 (en) | 2023-09-07 |
US20230142803A1 (en) | 2023-05-11 |
TW201732037A (zh) | 2017-09-16 |
EP3362075A4 (en) | 2019-04-17 |
NZ741612A (en) | 2022-12-23 |
JP2023171766A (ja) | 2023-12-05 |
JP2018535666A (ja) | 2018-12-06 |
CO2018004937A2 (es) | 2018-09-28 |
SG10201912576PA (en) | 2020-02-27 |
IL258666B1 (en) | 2024-05-01 |
CA3002066A1 (en) | 2017-04-20 |
JP2022023148A (ja) | 2022-02-07 |
BR112018007538A2 (pt) | 2018-10-23 |
EP3362075A1 (en) | 2018-08-22 |
AU2016340005A1 (en) | 2018-05-10 |
KR20180059555A (ko) | 2018-06-04 |
MX2018004600A (es) | 2019-09-04 |
US20180346877A1 (en) | 2018-12-06 |
EP3362075B1 (en) | 2023-06-07 |
SG11201803117YA (en) | 2018-05-30 |
CN109310710A (zh) | 2019-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201890960A1 (ru) | Натуральные киллеры и клетки ilc3 и их применение | |
EA201791443A1 (ru) | Естественные киллерные клетки и их применения | |
MX2015001871A (es) | Celulas asesinas naturales y usos de las mismas. | |
EA201990293A1 (ru) | Мультиспецифичные антитела против cd40 и cd137 | |
EA201991607A1 (ru) | Генетически модифицированные клетки-натуральные киллеры | |
MX2018012880A (es) | Metodos para proporcionar arn de hebra sencilla. | |
MD3433368T2 (ro) | Trans-replicarea ARN | |
EA201790413A1 (ru) | Антитела против tigit | |
BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
EA201790010A1 (ru) | Гамма-дельта t-клетки и их применение | |
EA201692473A1 (ru) | Способы получения замещенных нуклеотидных аналогов | |
EA201890079A1 (ru) | Клеточная система для направленной доставки активного ингредиента | |
EA202191508A1 (ru) | Размножение естественных клеток-киллеров и клеток ilc3 с использованием новых ароматических соединений | |
EA201891268A1 (ru) | Соединения, которые можно применять в качестве ингибиторов киназы | |
MX342995B (es) | Métodos de generar células asesinas naturales. | |
EA201790597A1 (ru) | Способы лечения вирусных инфекций filoviridae | |
EA201590085A1 (ru) | Антитела анти-egfr и их применение | |
EA201692512A1 (ru) | Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки | |
EA201800148A1 (ru) | Оспенная вакцина для лечения рака | |
EA201690898A1 (ru) | Способы лечения таупатии | |
EA201890572A1 (ru) | Биофармацевтические композиции | |
MA40458A (fr) | Méthodes de traitement du cancer du col de l'utérus | |
MX2021009554A (es) | Produccion de virus en cultivos celulares. | |
EA201691473A1 (ru) | Биспецифические анти-il-13/il-17 антитела и их применение | |
EA202091360A1 (ru) | Гуманизированные анти-liv1 антитела для лечения рака молочной железы |